[go: up one dir, main page]

PL3737668T3 - Sposób solubilizacji 5-amino-2,3-dihydro-1,4-ftalazynodionu - Google Patents

Sposób solubilizacji 5-amino-2,3-dihydro-1,4-ftalazynodionu

Info

Publication number
PL3737668T3
PL3737668T3 PL19701972.2T PL19701972T PL3737668T3 PL 3737668 T3 PL3737668 T3 PL 3737668T3 PL 19701972 T PL19701972 T PL 19701972T PL 3737668 T3 PL3737668 T3 PL 3737668T3
Authority
PL
Poland
Prior art keywords
phthalazinedione
solubilization
dihydro
amino
Prior art date
Application number
PL19701972.2T
Other languages
English (en)
Inventor
Ingo Saar
Wolfgang Brysch
Original Assignee
Metriopharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metriopharm Ag filed Critical Metriopharm Ag
Publication of PL3737668T3 publication Critical patent/PL3737668T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/32Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL19701972.2T 2018-01-11 2019-01-10 Sposób solubilizacji 5-amino-2,3-dihydro-1,4-ftalazynodionu PL3737668T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18000019.2A EP3511325A1 (en) 2018-01-11 2018-01-11 Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione
PCT/EP2019/000012 WO2019137825A1 (en) 2018-01-11 2019-01-10 Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione

Publications (1)

Publication Number Publication Date
PL3737668T3 true PL3737668T3 (pl) 2023-11-27

Family

ID=61094178

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19701972.2T PL3737668T3 (pl) 2018-01-11 2019-01-10 Sposób solubilizacji 5-amino-2,3-dihydro-1,4-ftalazynodionu

Country Status (15)

Country Link
US (2) US12122753B2 (pl)
EP (2) EP3511325A1 (pl)
JP (2) JP7446226B2 (pl)
KR (1) KR102734983B1 (pl)
CN (1) CN111587243B (pl)
AU (1) AU2019207332B2 (pl)
BR (1) BR112020013847A2 (pl)
CA (1) CA3084113A1 (pl)
ES (1) ES2952192T3 (pl)
HR (1) HRP20230766T1 (pl)
HU (1) HUE062433T2 (pl)
IL (1) IL275193B2 (pl)
MX (1) MX2020007467A (pl)
PL (1) PL3737668T3 (pl)
WO (1) WO2019137825A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3290026A1 (en) * 2016-09-06 2018-03-07 Athenion AG Method for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents
EP3511325A1 (en) * 2018-01-11 2019-07-17 MetrioPharm AG Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione
EP3870175B1 (en) * 2018-10-26 2024-08-28 Immunopharma Plus D.O.O. Oral aminodihydrophthalazinedione compositions and their use the treatment of non-viral hepatitis
US20220395547A1 (en) * 2019-11-08 2022-12-15 Vella Bioscience, Inc. Liposomal formulations for delivery of cannabinoids and methods of making thereof
BR112022019141A2 (pt) 2020-03-25 2023-01-17 Metriopharm Ag 5-amino-2,3-dihidro-1,4-ftalazinadiona para tratamento de lesão pulmonar aguda
JP2024516340A (ja) 2020-12-02 2024-04-15 メトリオファーム アーゲー Sars-cov-2感染の後遺症の予防と治療のためのルミノール
CN113384526A (zh) * 2021-08-03 2021-09-14 合肥医工医药股份有限公司 一种稳定的阿哌沙班口服溶液制剂及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857492A1 (de) * 1998-12-14 2000-06-15 Hans Lautenschlaeger Wasserhaltige Hautschutzpräparate zur Prävention von Hautschäden
US6441050B1 (en) * 2000-08-29 2002-08-27 Raj K. Chopra Palatable oral coenzyme Q liquid
DE10133305B4 (de) 2001-07-12 2004-06-03 Aquanova German Solubilisate Technologies (Agt) Gmbh Ubichinon Konzentrat
WO2003090717A1 (en) 2002-04-23 2003-11-06 Nanotherapeutics, Inc Process of forming and modifying particles and compositions produced thereby
RU2245138C1 (ru) * 2003-10-21 2005-01-27 Общество с ограниченной ответственностью "Абидофарма" Способ лечения глазных заболеваний и глазные капли и глазная мазь для его осуществления
JP2009513642A (ja) 2005-10-25 2009-04-02 アボット・ラボラトリーズ 低水溶解度の薬剤を含む製剤およびそれの使用方法
US20080145411A1 (en) * 2006-10-06 2008-06-19 Kaneka Corporation Composition of high absorbability for oral administration comprising oxidized coenzyme q10
WO2008097953A2 (en) 2007-02-05 2008-08-14 Wyeth Pharmaceutical compositions containing substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
AU2009282659A1 (en) 2008-08-18 2010-02-25 Nanotherapeutics, Inc. Topical hydrogel composition
PL231885B1 (pl) 2009-01-16 2019-04-30 Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie
WO2010091257A1 (en) * 2009-02-06 2010-08-12 Bach Pharma, Inc. Pharmaceutical grade phthalazinediones, process for their preparation and pharmaceutical compositions containing them
EP2243517A1 (de) * 2009-04-20 2010-10-27 Dr. Straetmans GmbH Kosmetische oder dermatologische Zubereitung
HRP20140752T1 (hr) 2010-03-01 2014-10-24 Metriopharm Ag Kristalni oblici 5-amino-2,3-dihidroftalazin-1,4-dion natrijeve soli, farmaceutski pripravci koji ih sadrže i postupak za njihovu proizvodnju
US8871811B2 (en) * 2011-02-07 2014-10-28 Professional Compounding Centers of America, Ltd Permeation enhancers for topical formulations
WO2013108254A1 (en) 2012-01-19 2013-07-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Formulation and method for increasing oral bioavailability of drugs
DE202012012130U1 (de) 2012-12-19 2014-03-21 Aquanova Ag Curcuminsolubilisat
WO2016096143A1 (de) 2014-12-18 2016-06-23 Metriopharm Ag Kristalline form von 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
EP3416951B1 (en) * 2016-02-16 2020-04-08 MetrioPharm AG Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione
KR102535959B1 (ko) * 2016-02-16 2023-05-23 메트리오팜 아게 5-아미노-2,3-디하이드로프탈라진-1,4-디온의 결정질 형태를 제조하는 방법
EP3248602A1 (en) * 2016-05-26 2017-11-29 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae
EP3290026A1 (en) * 2016-09-06 2018-03-07 Athenion AG Method for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents
EP3511325A1 (en) * 2018-01-11 2019-07-17 MetrioPharm AG Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione

Also Published As

Publication number Publication date
KR20200108864A (ko) 2020-09-21
US20210061771A1 (en) 2021-03-04
IL275193B1 (en) 2024-04-01
CN111587243B (zh) 2024-04-12
HRP20230766T1 (hr) 2023-10-27
JP7762245B2 (ja) 2025-10-29
US20250051288A1 (en) 2025-02-13
CN111587243A (zh) 2020-08-25
NZ764957A (en) 2024-07-05
AU2019207332B2 (en) 2023-09-28
IL275193B2 (en) 2024-08-01
JP7446226B2 (ja) 2024-03-08
RU2020118910A (ru) 2022-02-11
IL275193A (en) 2020-07-30
KR102734983B1 (ko) 2024-11-26
JP2024059864A (ja) 2024-05-01
JP2021511301A (ja) 2021-05-06
EP3737668A1 (en) 2020-11-18
EP3737668B1 (en) 2023-06-07
EP3737668C0 (en) 2023-06-07
WO2019137825A1 (en) 2019-07-18
HUE062433T2 (hu) 2023-11-28
BR112020013847A2 (pt) 2021-03-02
CA3084113A1 (en) 2019-07-18
MX2020007467A (es) 2020-09-14
US12122753B2 (en) 2024-10-22
AU2019207332A1 (en) 2020-06-18
ES2952192T3 (es) 2023-10-30
EP3511325A1 (en) 2019-07-17

Similar Documents

Publication Publication Date Title
PL3737668T3 (pl) Sposób solubilizacji 5-amino-2,3-dihydro-1,4-ftalazynodionu
IL292754A (en) Method of synthesis
HUE059594T2 (hu) Hírvivõ RNS tisztítására szolgáló eljárások
DK3665173T3 (da) Ny fremgangsmåde til yntetisering af amanitiner
MA53180A (fr) Méthode de génération d'un descendance stérile
EP3948333A4 (en) LIDAR AND ASSOCIATED ADJUSTMENT METHOD
IL285546A (en) Compounds and methods for reducing kcnt1 expression
EP3752631A4 (en) CHARGE-LABEL NUCLEOTIDES AND THEIR METHODS OF USE
EP3953090C0 (de) Reibahle
EP3553060A4 (en) POLYCRYSTALLINE MESYLATE OF PHOSPHODIESTERASE TYPE-5 INHIBITOR, METHOD OF MANUFACTURING THEREOF AND THE APPLICATION THEREOF
EP3980515C0 (en) ROASTING PROCESS
EP3817575C0 (de) Solubilisierung schwerlöslicher kühlsubstanzen
DK3164385T3 (da) Ny polymorf form af n-[2-(6-fluor-lh-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluorpropoxy)benzylaminhydrochlorid for behandlingen af alzheimers
EP3937031A4 (en) SEARCH DEVICE, SEARCH APPLICATION AND SEARCH METHOD
UA42377S (uk) Комплект етикеток
UA42366S (uk) Комплект етикеток
UA42073S (uk) Комплект етикеток
UA41330S (uk) Комплект етикеток
UA40681S (uk) Комплект етикеток
UA41684S (uk) Комплект етикеток
UA40980S (uk) Комплект етикеток
UA40553S (uk) Комплект етикеток
UA40315S (uk) Комплект етикеток
UA41014S (uk) Комплект етикеток
UA40551S (uk) Комплект етикеток